We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

80 hedge funds and large institutions have $308M invested in Xenon Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 16 increasing their positions, 27 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

1% more funds holding

Funds holding: 79 → 80 (+1)

0.16% less ownership

Funds ownership: 79.95% → 79.79% (-0.16%)

12% less capital invested

Capital invested by funds: $351M → $308M (-$42.7M)

41% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 27

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
80
Holders Change
+1
Holders Change %
+1.27%
% of All Funds
1.61%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
6
Increased
16
Reduced
27
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$5.01M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$5M
3
SCM
Soleus Capital Management
Connecticut
+$2.93M
4
GIM
Granahan Investment Management
Massachusetts
+$561K
5
Goldman Sachs
Goldman Sachs
New York
+$385K

Top Sellers

Rank Fund Capital Flow
1
ACP
Acuta Capital Partners
California
-$2.56M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$2.5M
3
Renaissance Technologies
Renaissance Technologies
New York
-$1.55M
4
PHP
Parkman Healthcare Partners
Connecticut
-$1.48M
5
JP Morgan Chase
JP Morgan Chase
New York
-$1.21M
Name Holding Trade Value Shares
Change 		Change in
Stake
DMK
26
David M. Knott
$1.96M +$94.1K +8,000 +5%
AGA
27
Altrinsic Global Advisors
Connecticut
$1.88M – – –
GIM
28
Granahan Investment Management
Massachusetts
$1.76M +$561K +47,705 +43%
AS
29
Altshuler Shaham
Israel
$1.67M – – –
GPCM
30
Granite Point Capital Management
Massachusetts
$1.57M – – –
Two Sigma Advisers
31
Two Sigma Advisers
New York
$1.17M +$56.5K +4,800 +5%
Vanguard Group
32
Vanguard Group
Pennsylvania
$1.05M +$1.76K +150 +0.2%
State Street
33
State Street
Massachusetts
$991K +$33.9K +2,883 +3%
Acadian Asset Management
34
Acadian Asset Management
Massachusetts
$915K +$256K +21,789 +36%
California Public Employees Retirement System
35
California Public Employees Retirement System
California
$861K -$3.75K -319 -0.4%
BlackRock
36
BlackRock
New York
$763K -$2.95K -251 -0.4%
SSA
37
Schonfeld Strategic Advisors
New York
$693K +$318K +27,000 +76%
Swiss National Bank
38
Swiss National Bank
Switzerland
$692K – – –
Northern Trust
39
Northern Trust
Illinois
$690K +$8.45K +718 +1%
Goldman Sachs
40
Goldman Sachs
New York
$686K +$385K +32,694 +112%
Two Sigma Investments
41
Two Sigma Investments
New York
$553K -$825K -70,130 -58%
PNC Financial Services Group
42
PNC Financial Services Group
Pennsylvania
$506K – – –
AA
43
ALPS Advisors
Colorado
$494K -$36.2K -3,080 -6%
HS
44
HighVista Strategies
Massachusetts
$482K +$274K +23,278 +115%
SC
45
Scotia Capital
Ontario, Canada
$462K +$1.97K +167 +0.4%
Royal Bank of Canada
46
Royal Bank of Canada
Ontario, Canada
$452K – – –
Marshall Wace
47
Marshall Wace
United Kingdom
$413K -$536K -45,567 -55%
BFM
48
Boothbay Fund Management
New York
$404K -$96.1K -8,167 -18%
Deutsche Bank
49
Deutsche Bank
Germany
$337K – – –
SMH
50
Sanders Morris Harris
Texas
$288K +$288K +24,500 New
1
2
3 4

XENE Hedge Fund Activity: Q3 2020 in Review

80 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q3 2020, worth a combined $308M — down 12% from $351M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new XENE positions and 5 closed out — a net gain of 1 holder — while 16 added to existing stakes and 27 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $5.01M. The largest seller was Acuta Capital Partners, cutting an estimated $2.56M.

  • 80 institutional investors held Xenon Pharmaceuticals (XENE) as of Q3 2020, up from 79 in Q2 2020.
  • Funds reported $308M of Xenon Pharmaceuticals stock for Q3 2020, down 12% quarter-over-quarter.
  • 6 funds opened new Xenon Pharmaceuticals positions in Q3 2020 and 5 closed out, a net change of +1 holder.
  • The largest Xenon Pharmaceuticals buyer in Q3 2020 was Fidelity Investments, an estimated $5.01M added.
  • The largest Xenon Pharmaceuticals seller in Q3 2020 was Acuta Capital Partners, an estimated $2.56M sold.

Based on aggregated 13F filings for Q3 2020.